Clinical trials: Advanced Gastric Adenocarcinoma
Gastro-Oesophageal Cancer
A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer
A randomised phase III, double-blind, placebo-controlled trial with 2:1 (regorafenib : placebo)
- Trial name
- INTEGRATEIIa (NCT02773524)
- Testing
- Regorafenib
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 250 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Gastric Cancer
Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair Deficiency
Study Background 1. Clinical Rationale and Unmet Medical Need Gastric cancer is the 5th most common malignancy and the 3rd leading cause of cancer death worldwide.
- Trial name
- NCT07595523
- Testing
- Iparomlimab/Tuvonralimab (QL1706)
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Solid Tumor, Cholangiocarcinoma
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04742959
- Testing
- TT-00420, Nab-Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 203 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Hepatoid Adenocarcinoma of Stomach
Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach
The goal of this clinical trial is to learn if treatment modality including Disitamab Vedotin （RC48）, Oxaliplatin，Tegafur,Gimeracil and Oteracil Porassium Capsules （SOX）and Sindillimab works to treat locally advanced hepatoid…
- Trial name
- HASCHANGE01 (NCT06992362)
- Testing
- Perioperative treatment
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07284186
- Testing
- PLX-61639
- Where
- 10 sites in United States
- Volunteers
- 155 people
- Sponsor
- Plexium, Inc.
Gastric Cancer
Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma
To study the efficacy and safety of camrelizumab combined with SOX regimen for adjuvant therapy of stage III gastric cancer
- Trial name
- NCT05184946
- Testing
- Camrelizumab Combined with SOX
- Where
- China
- Volunteers
- 72 people
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03621982
- Testing
- ADCT-301, Pembrolizumab
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 78 people
- Sponsor
- ADC Therapeutics S.A.
Esophageal Cancer, Gastric Cancer
Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00020787
- Testing
- G17DT Immunogen, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors.
- Conditions
- Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
- Trial name
- NCT04895709
- Testing
- BMS-986340, BMS-936558-01, Docetaxel
- Where
- 47 sites in United States, Australia and 6 more
- Volunteers
- 1,109 people
- Sponsor
- Bristol-Myers Squibb
Stomach Neoplasms
Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer
XELOX regimen had a more favorable toxicity profile compared to cisplatin for patients with advanced gastric cancer. The safety profile of oxaliplatin makes it an ideal candidate for combination therapy.
- Trial name
- NCT02289547
- Testing
- Capecitabine
- Where
- 8 sites in South Korea
- Volunteers
- 184 people
- Sponsor
- The Catholic University of Korea
Gastric Cancer
Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00683787
- Testing
- docetaxel, vandetanib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma
Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial
This study is to evaluate the efficacy and safety of domestic programmed death 1（ PD-1） antibody (Camrelizumab for injection) combined with fluorouracil plus leucovorin, oxaliplatin, and albumin bound paclitaxel (Nab-POF) regimen…
- Conditions
- Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma, Gastric Cancer Adenocarcinoma Metastatic
- Trial name
- NCT04510064
- Testing
- Camrelizumab plus mFLOT regimen, R0 surgery
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Metastatic Cancer, Melanoma
Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
This study evaluated the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced or metastatic cancer
- Conditions
- Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- ConsortiumIO (NCT04208958)
- Testing
- VE800, Nivolumab, Vancomycin Oral Capsule
- Where
- 18 sites in United States
- Volunteers
- 56 people
- Sponsor
- Vedanta Biosciences, Inc.
HER2-positive Gastric Cancer, Metastatic Cancer
Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients
The purpose of this retrospective study is to evaluate the efficacy and the safety of trastuzumab + chemotherapies with or without taxanes among HER2-positive advanced gastroesophageal adenocarcinoma patients.
- Conditions
- HER2-positive Gastric Cancer, Metastatic Cancer, Docetaxel, Trastuzumab
- Trial name
- TandHER (NCT04920747)
- Testing
- Taxane
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Advanced Solid Tumor, Gastric Cancer
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05159440
- Testing
- TORL-2-307-MAB
- Where
- 8 sites in United States, South Korea
- Volunteers
- 70 people
- Sponsor
- TORL Biotherapeutics, LLC
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
The study is being conducted to evaluate the efficacy, safety and tolerability of radiotherapy and chemotherapy, apatinib with camrelizumab in the neoadjuvant (prior to surgery) and adjuvant (after surgery) treatment of…
- Trial name
- NCT07026149
- Testing
- Apatinib+Camrelizumab+SOX, Preoperative Radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma
This is a phase III, multi-Center, randomized, placebo-controlled trial to investigate the efficacy and safety of CS1001 in combination with Oxaliplatin and Capecitabine (CAPOX) chemotherapy in first-line subjects with…
- Trial name
- NCT03802591
- Testing
- CS1001 monoclonal antibody, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 479 people
- Sponsor
- CStone Pharmaceuticals
Esophageal Cancer, Gastric Cancer
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally…
- Trial name
- NCT00005876
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Colorectal Cancer, Gastric Cancer
TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of orally administered TT-4 in subjects with advanced selected solid tumors.
- Conditions
- Colorectal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Pancreatic Cancer
- Trial name
- NCT04976660
- Testing
- TT-4
- Sponsor
- Tarus Therapeutics, Inc.